3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine | 34583-80-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine
• 英文别名: 3-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine；3-methyl-2,3,4,5-tetrahydro-1H-benz[d]azepine；3-Methyl-2,3,4,5-tetrahydro-1H-benz[d]azepin；1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine；3-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine；N-Methyl-2,3,4,5-tetrahydro-1H-3-benzazepin；3-Methyl-1,2,4,5-tetrahydro-3-benzazepine
• CAS: 34583-80-7
• 化学式: C₁₁H₁₅N
• 分子量: 161.247
• InChiKey: LIELBBMDHOZRFL-UHFFFAOYSA-N

物化性质

• 沸点：
  237 °C
• 密度：
  0.976±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine 、 氯苯 在 仲丁基锂 作用下， 以 四氢呋喃 、 正戊烷 为溶剂， 反应 1.0h， 以27%的产率得到2,3,4,5-tetrahydro-3-methyl-1-phenyl-1H-3-benzoazepine
  参考文献：
  名称：

  Aryne-Mediated Arylation of the 3-Benzazepine Scaffold: One-Pot Synthesis of 1-Aryl-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepines

  摘要：

  The coupling of beta-amino carbanions derived from 3-benzazepines with in situ generated arynes has been demonstrated as a convenient route for the direct synthesis of a variety of 1-aryl-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepines, including the biologically active drug molecule SCH 12679.

  DOI：

  10.1055/s-0034-1380453
• 作为产物：
  描述：

  3-formyl-1-phenylsulfanyl-2,3,4,5-tetrahydro-1H-3-benzazepine 在 sodium tetrahydroborate 、 lithium aluminium tetrahydride 、 nickel dichloride 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 7.33h， 生成 3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine
  参考文献：
  名称：

  A Synthesis of 2,3,4,5-Tetrahydro-1H-3-benzazepines via Pummerer-Type Cyclization of N-(2-Arylethyl)-N-(2-phenylsulfinylethyl)formamides

  摘要：

  DOI：

  10.3987/com-00-8982

文献信息

• HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20190315766A1

  公开（公告）日：2019-10-17

  The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了式（I）的化合物，以及其药学上可接受的盐、酯或前药： 这些化合物抑制呼吸道合胞病毒（RSV）。本发明还涉及包含上述化合物的药物组合物，用于治疗患有RSV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的RSV感染的方法。
• Dihydrothienopyrimidines
  申请人：GERLACH Kia

  公开号：US20130196988A1

  公开（公告）日：2013-08-01

  The present invention relates to dihydrothienopyrimidines, their use as modulators of γ-secretase and to pharmaceutical compositions containing said compounds. In particular, the present invention relates to compounds which interfere with γ-secretase and/or its substrate and therefore modulate the formation of Aβ peptides.

  本发明涉及二氢噻吡嘧啶类化合物，其作为γ-分泌酶调节剂的用途，以及含有这些化合物的药物组合物。具体而言，本发明涉及干扰γ-分泌酶和/或其底物的化合物，从而调节Aβ肽的形成。
• [EN] CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS<br/>[FR] PYRIMIDINES CYCLOALKYLIQUES UTILISÉES EN TANT QU'INHIBITEURS DE LA FERROPORTINE
  申请人：GLOBAL BLOOD THERAPEUTICS INC

  公开号：WO2021222363A1

  公开（公告）日：2021-11-04

  The subject matter described herein is directed to ferroportin inhibitor compounds of Formula I or I' and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.

  本文描述的主题涉及Formula I或I'的铁蛋白抑制剂化合物及其药用盐，制备这些化合物的方法，包含这些化合物的药物组合物，以及用于预防和/或治疗由于缺乏肝铁蛋白或铁代谢紊乱引起的疾病的方法，特别是铁过载状态，如地中海贫血、镰状细胞病和血色病，以及肾脏损伤。
• [EN] METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS<br/>[FR] MÉTHODES D'UTILISATION DE PYRIMIDINES EN TANT QU'INHIBITEURS DE LA FERROPORTINE
  申请人：GLOBAL BLOOD THERAPEUTICS INC

  公开号：WO2021222483A1

  公开（公告）日：2021-11-04

  The subject matter described herein is directed to ferroportin inhibitor compounds of Formula (I) and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.

  本文描述的主题是针对化学式(I)的铁蛋白抑制剂化合物及其药用盐，制备这些化合物的方法，包含这些化合物的药物组合物，以及用于预防和/或治疗由于缺乏肝铁蛋白或铁代谢紊乱引起的疾病的方法，特别是铁超载状态，如地中海贫血、镰状细胞病和血色病，以及肾损伤。
• COMPOUNDS
  申请人：HEER Jag Paul

  公开号：US20100174065A1

  公开（公告）日：2010-07-08

  The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.

  本发明涉及具有药理活性的新型噁二唑衍生物，其制备方法，含有它们的药物组合物以及它们在治疗各种疾病中的用途。